The Molecular Recognition Shared Resource (MRSR) is a newly established core facility. The goal of the MRSR is to provide investigators with reagents, equipment, and expertise for the production, detection and characterization of biomolecules. The MRSR is composed of three individual Resources , the Antibody Resource, the Protein Expression Resource and the BIAcore Resource. Each of these resources provides unique, cost- effective services and expertise for Vanderbilt Cancer Center (VCC) and University Investigators. The goals and the objectives of three resources are described below. The goal of the Antibody Resource is to provide the expertise, reagents and equipment for the production, detection, characterization, purification and labeling of traditional polyclonal, monoclonal and phage-displayed or soluble ScFv recombinant antibodies. Assays incorporating antibodies can also be developed to detect and/or quantitate proteins, carbohydrates or nucleic acids which occur individually or as components of a biological milieu. The objective of the Antibody Resource is to provide antibodies and antibody-based assays to VCC and University Investigators on a timely and cost-effective basis. The goal of the Protein Expression Resource is to provide VCC and University Investigators with reagents and equipment for large scale protein expression using the baculovirus expression system. Additionally, Investigators are provided with equipment necessary to harvest large amounts of cellular material. The goal and objective of the BIAcore Resource is to provide VCC and University Investigators with access to the BIAcore 2000, an instrument from BIAcore, AB., that performs real-time biomolecular interaction analysis using surface plasmon resonance technology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-07
Application #
6652751
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-09-01
Project End
2003-08-31
Budget Start
Budget End
Support Year
7
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37203
Burns, Michael C; Howes, Jennifer E; Sun, Qi et al. (2018) High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling. Anal Biochem 548:44-52
Phelps, Hannah M; Al-Jadiry, Mazin F; Corbitt, Natasha M et al. (2018) Molecular and epidemiologic characterization of Wilms tumor from Baghdad, Iraq. World J Pediatr 14:585-593
Liu, Qi; Herring, Charles A; Sheng, Quanhu et al. (2018) Quantitative assessment of cell population diversity in single-cell landscapes. PLoS Biol 16:e2006687
Almodovar, Karinna; Iams, Wade T; Meador, Catherine B et al. (2018) Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse. J Thorac Oncol 13:112-123
Greenplate, Allison; Wang, Kai; Tripathi, Rati M et al. (2018) Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies. JCO Precis Oncol 2018:
Mi, Deborah J; Dixit, Shilpy; Warner, Timothy A et al. (2018) Altered glutamate clearance in ascorbate deficient mice increases seizure susceptibility and contributes to cognitive impairment in APP/PSEN1 mice. Neurobiol Aging 71:241-254
Diggins, Kirsten E; Gandelman, Jocelyn S; Roe, Caroline E et al. (2018) Generating Quantitative Cell Identity Labels with Marker Enrichment Modeling (MEM). Curr Protoc Cytom 83:10.21.1-10.21.28
Warner, Jeremy L; Prasad, Ishaan; Bennett, Makiah et al. (2018) SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine. JCO Precis Oncol 2018:
Brown, Judy J; Short, Sarah P; Stencel-Baerenwald, Jennifer et al. (2018) Reovirus-Induced Apoptosis in the Intestine Limits Establishment of Enteric Infection. J Virol 92:
Iams, Wade T; Yu, Hui; Shyr, Yu et al. (2018) First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer 19:531-543

Showing the most recent 10 out of 2462 publications